GARFIELD-VTE Registry

GARFIELD-VTE registry

GARFIELD-VTE observed treatment and outcomes in patients with acute venous thromboembolism in the real world

Keep Up to Date Login
Menu
  • Home
      • Explore the tree

        For a summary of our published findings, explore the GARFIELD tree either by clicking on the branches or by using the navigation links below.

        • Burden of Disease
        • Cancer-Associated Thrombosis
        • Treatment Patterns
        • Clinical Outcomes
        • Patient Reported Outcomes
        • Geographic Differences
        • Health Economics
    Close
  • About
    • About GARFIELD-VTE
    • Our Governance
    • About VTE
    • External Links
    • Close
  • Publications & Presentations
  • Newsletters
  • Media
  • Community Page

About VTE

Venous blood clots in the deep veins (DVT) or lungs (PE) remain a medical emergency, killing one person every 37 seconds in the Western World.

Venous Thromboembolism (VTE) occurs when part of a clot formed in a deep vein, for example in the leg (known as deep vein thrombosis, or DVT), is carried to the lung, via the heart, preventing the uptake of oxygen. This is known as a pulmonary embolism (PE), an event which can be rapidly fatal.

VTE is the third most common cardiovascular illness, after acute coronary syndrome and stroke, responsible for approximately 780,000 deaths in the Europe and United States each year. In around 90% of fatal cases the embolism is undetected or untreatable prior to death, making VTE-prevention an essential task for every health care system.

In patients with PE, up to 25% of patients present with sudden death and a further 15-20% die within three months. In patients with DVT, 60% of patients develop post-thrombotic syndrome (PTS), the symptoms of which include pain, swelling, varicose veins and skin discolouration. 3-4% of patients develop venous ulcers, which are chronic wounds that require dressing and compression.

Both PTS and venous ulcers have a significant impact on a patient’s quality of life, and are associated with significant direct and indirect costs. The total cost of VTE treatment and management is estimated to be £640 million per year in the United Kingdom.

New oral anticoagulants have been developed to serve as a single-drug solution approved for the treatment and subsequent prevention of VTE, providing simplified patient management without the need for injections or routine coagulation monitoring. Xarelto (rivaroxaban) was the first such single-drug solution approved for the treatment of DVT and the prevention of recurrent DVT and PE in 2011.

As many as one in four VTEs occur in patients with a previous VTE. The estimated increasing risk of recurrence in unprovoked VTE is 10% at one year and 30% at 10 years. Both morbidity and mortality are increased with recurrent VTE.

The traditional standard of care for acute VTE treatment and long-term prevention of recurrence is a dual-drug approach of daily injections of a low molecular weight heparin (LMWH) followed by a transition to long-term oral anticoagulant therapy with a vitamin K antagonist (VKA), such as warfarin.

Community members, please login to view additional information

About

About GARFIELD-VTE

GARFIELD-VTE explored acute and long-term management and outcomes in patients with symptomatic... [read more]

20 Jan 22
About

Our Governance

The Steering Committee, supported by the National Coordinator Council, provides global leadership... [read more]

21 Sep 17

Global Status

Read more
Total patients 10,869
Recruitment Recruitment closed
Follow-up Follow-up ongoing
Study end: 2020

Contact Us

To find out more about GARFIELD-VTE, please contact the Thrombosis Research Institute.

info@tri-london.ac.uk Contact Us

Follow Us

Keep Up to Date

Sign-up to our newsletter to receive news and updates from us

Keep Up to Date

Funding

The GARFIELD-VTE registry was funded by an unrestricted research grant from Bayer AG, and the ongoing work is supported by the Thrombosis Research Institute.

© Copyright TRI 2023

All Rights Reserved. No part of this site may be reproduced without our permission.

  • About TRI
  • Cookie Notice
  • Privacy Policy
  • Terms of Use

Members Login

Coming soon… If you would like to be notified of when this is available click here and add your details to receive updates

Newsletter Signup






    Please see our Privacy Policy and Cookie Policy

    Contact Us

      To find out more about GARFIELD-VTE, please contact the Thrombosis Research Institute

      E: garfield@tri-london.ac.uk
      T: 0203 198 9947